ExeVir Bio

Foundation date

10/07/2020

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including pan-coronaviruses. It is a spin out from VIB, the world class Belgium-based life sciences research institute. ExeVir’s platform is based on the work of and collaboration with Professor Dr. Xavier Saelens and Professor Dr. Nico Callewaert from VIB.

Upcoming events

Latest news

  • Imec-onderzoekers leggen basis voor in vivo detectie van traag groeiende hersentumoren, met dank aan hyperspectrale camera

    Friday February 3rd 2023

  • Weber joins Vivactis Group to reinforce its Market Access capabilities

    Thursday February 2nd 2023

  • Mithra CDMO announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health

    Thursday February 2nd 2023